Hepatitis C Articles (HCV)
Back
	Ledipasvir/Sofosbuvir HIV/HCV Coinfection Phase 3 Study Ongoing       A Phase 3, Multicenter, Open-Label Study....Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection....in US estimated enrollment 300......https://clinicaltrials.gov/ct2/show/NCT02073656?term=ledipasvir+HIV+coinfection&rank=2   This study is ongoing, but not recruiting participants; Sponsor: Gilead This study will evaluate the antiviral efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) administered for 12 weeks in hepatitis C virus (HCV) treatment-naive and treatment-experienced (including treatment intolerant) participants with chronic genotype 1 or 4 HCV infection who are co-infected with HIV-1.   Participants who experience confirmed post-treatment virologic failure (relapse) at or before posttreatment Week 24 may be eligible to be enrolled in the Retreatment Substudy. Sponsor: Gilead Sciences   ClinPharmWk: Drug Interactions Between Direct-Acting anti-HCV Antivirals Sofosbuvir and Ledipasvir and HIV Antiretrovirals - (05/27/14)   ClinPharmWk: Effect of Food and Acid Reducing Agents on the Relative Bioavailability and Pharmacokinetics of Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet - (05/27/14)           View Older Articles   Back to Top   www.natap.org